With some saying that the government’s focus on UK investment has brought a renewed sense of optimism and stability to the tax-efficient investment space, Isabel Baxter explores if advisers need to utilise these schemes more…
Laverock Therapeutics, which is growing fast from its base at Stevenage Bioscience Catalyst, has unveiled Ali Elsley as Finance Director and revealed significant expansion of its team.
MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a £7 million Series A financing round, led by Mercia Ventures.